Is Osimertinib mesylate tablets an imported drug?

Osimertinib mesylate (Osimertinib) tablets are imported drugs. This drug was originally developed and produced by the foreign company AstraZeneca and approved for marketing by the U.S. Food and Drug Administration (FDA). According to FDA-approved trials, osimertinib is suitable for adjuvant treatment after tumor resection in adult patients with non-small cell lung cancer (NSCLC), and is also used for the first-line treatment of EGFR mutation-positive metastatic NSCLC and previously treated EGFR T790M mutation-positive metastatic NSCLC.

Osimertinib is an epidermal growth factor receptor (EGFR) kinase inhibitor that irreversibly binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at concentrations approximately 9-fold lower than wild type. After oral administration of osimertinib, two pharmacologically active metabolites with inhibitory properties similar to those of osimertinib were found in plasma. AZ7550 showed similar potency to osimertinib, while AZ5104 showed stronger potency against exon 19 deletion and T790M mutant and wild-type EGFR. In vitro, osimertinib also inhibits the activities of HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.

Osimertinib The original drug has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may be different. Specification The price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.